Study Questions Benefits of New Alzheimer’s Drugs as Evidence Mounts Against Clinical Efficacy

The European Medicines Agency has defended the continued use of amyloid-targeting Alzheimer’s drugs despite a recent analysis questioning their clinical benefit, emphasizing that treatment decisions should remain individualized based on patient needs and physician judgment.

The defense came in response to a Cochrane Collaboration review that concluded amyloid-clearing drugs provide no clinically meaningful cognitive benefit and may increase risks of brain swelling and bleeding. The review analyzed 17 trials of seven medicines, finding effects at 18 months were absent or trivial on standard cognitive tests.

Several U.S. Experts have criticized the Cochrane analysis, arguing it unfairly combined data from failed drugs with two recently approved treatments that have shown positive results in certain patient populations. These experts contend that the methodology diminishes the value of drugs that may benefit specific individuals and advocate for personalized treatment approaches rather than broad conclusions about drug class effectiveness.

The EMA’s position reflects ongoing regulatory scrutiny of Alzheimer’s therapies amid conflicting evidence about their real-world impact. While acknowledging the concerns raised by the analysis, the agency maintains that healthcare providers should weigh potential benefits against risks when considering these treatments for patients in the early stages of Alzheimer’s disease.